How should a mid-cap biotech structure its first outsourced safety contract in the Pharmacovigilance Market?

Start with a hybrid scope: outsource intake and coding, retain medical review internally. Cap volume assumptions with a renegotiation trigger at 30% variance, because launch case volumes are notoriously mis-forecast [9]. Read More

What due diligence matters most when selecting a provider?

Request inspection history — specifically findings from FDA and EMA audits over five years, not just certifications. A provider's remediation record predicts your inspection outcome better than any capability deck [1]. Read More

Does the Pharmacovigilance Market favour platform vendors or service providers for long-term contracts?

Platform vendors offer lower switching flexibility but better unit economics past year three. Service providers suit organizations with volatile pipelines. Portfolio predictability should decide it [15]. Read More

How do AI-assisted safety systems affect regulatory inspection risk?

Inspectors examine model governance, validation evidence and human-oversight documentation rather than algorithm performance itself. Undocumented model updates are the most common finding [16]. Read More

What integration challenges arise when merging safety databases after an acquisition?

Case-numbering conflicts and divergent coding conventions cause most delays. Budget nine to fifteen months and plan for parallel operation, since regulators will not accept a reporting gap [15]. Read More

Which emerging use case will reshape the Pharmacovigilance Market fastest?

Wearable and app-sourced continuous monitoring in decentralized trials. No standard exists yet for triaging device-generated signals, so early frameworks will likely become de facto requirements [10]. Read More

How should buyers evaluate pricing when providers quote different models?

Normalize every bid to fully loaded cost per medically confirmed serious case over a three-year horizon. Per-FTE and per-case quotes hide volume risk that shifts entirely onto the sponsor [9]. Read More

Pharmacovigilance Market (2025 - 2035)

ID: MRFR/HC/6979-HCR 200 Pages Nidhi Mandole Last Updated: September 15, 2026

Pharmacovigilance Market Research Report: Size, Share, Trend Analysis By Service Type (Adverse Event Reporting, Risk Assessment, Data Mining, Pharmacovigilance Consulting), By Deployment Mode (Cloud-Based, On-Premise), By Source (Spontaneous Reporting, Literature Reports, Scheduled Reporting), By End Users (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Pharmacovigilance Market

Market Size

Forecast Period2025-2035

CAGR (2025-2035)12.5%

2025 Market SizeUSD 9.96 Billion

2035 Market SizeUSD 32.13 Billion

Key Players

IQVIA

Accenture

Cognizant

ICON plc

Oracle Health Sciences

Parexel

Trends

Complex Modalities Are Rewriting Safety Economics
Regulatory Timelines Keep Compressing
Automation Turns a Cost Centre Into Leverage

Opportunities

Signal Detection as a Standalone Service Line
Emerging-Market Capacity Buildout
Monetizing De-identified Safety Data

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Report Takeaways |
1. 2.1 By Service Delivery Model |
2. 2.2 By Reporting Method and End User |
3. 2.3 By Geography
3 Global Market Size & Forecast (2021–2035) |
1. 3.1 Historical Market Size (2021–2025) |
2. 3.2 Current & Forecast Market Size (2026–2035) |
3. 3.3 Market Size by Revenue (USD Billion) |
4. 3.4 Year-over-Year Growth Analysis
4 Driver Impact Analysis |
1. 4.1 Complex Modalities and Safety Economics |
2. 4.2 Compressing Regulatory Timelines |
3. 4.3 Automation and Operating Leverage |
4. 4.4 Outsourcing Economics and Scale
5 Restraints Impact Analysis |
1. 5.1 Data Sovereignty and Cross-Border Restrictions |
2. 5.2 Safety Talent Scarcity |
3. 5.3 Legacy Migration Risk
6 Opportunity Analysis |
1. 6.1 Signal Detection as a Standalone Service Line |
2. 6.2 Emerging-Market Capacity Buildout |
3. 6.3 Monetizing De-identified Safety Data |
4. 6.4 Medical Device and Combination Product Convergence |
5. 6.5 Decentralized Trial Safety Infrastructure |
6. 6.6 Industry Value Chain Analysis |
7. 6.7 Porter's Five Forces Analysis
7 Regional Market Share & Country-Level Analysis |
1. 7.1 North America | |
  1. 7.1.1 US | |
  2. 7.1.2 Canada | |
  3. 7.1.3 Mexico |
2. 7.2 Europe | |
  1. 7.2.1 Germany | |
  2. 7.2.2 UK | |
  3. 7.2.3 France | |
  4. 7.2.4 Italy | |
  5. 7.2.5 Spain | |
  6. 7.2.6 Nordic Countries | |
  7. 7.2.7 Russia | |
  8. 7.2.8 Rest of Europe |
3. 7.3 Asia-Pacific | |
  1. 7.3.1 China | |
  2. 7.3.2 India | |
  3. 7.3.3 Japan | |
  4. 7.3.4 South Korea | |
  5. 7.3.5 ASEAN | |
  6. 7.3.6 Rest of Asia-Pacific |
4. 7.4 South America | |
  1. 7.4.1 Brazil | |
  2. 7.4.2 Argentina | |
  3. 7.4.3 Rest of South America |
5. 7.5 Middle East & Africa | |
  1. 7.5.1 Saudi Arabia | |
  2. 7.5.2 UAE | |
  3. 7.5.3 South Africa | |
  4. 7.5.4 Egypt | |
  5. 7.5.5 Rest of Middle East & Africa
8 Future Outlook (2026–2035) |
1. 8.1 Autonomous Case Processing and Regulatory Acceptance |
2. 8.2 Platform Economics and Pricing Model Shift |
3. 8.3 Real-World Evidence as Primary Surveillance Substrate |
4. 8.4 Convergence With Health Economics and Payer Evidence
9 Market Segmentation Analysis |
1. 9.1 By Clinical Trial Phase | |
  1. 9.1.1 Pre-Clinical | |
  2. 9.1.2 Phase I | |
  3. 9.1.3 Phase II | |
  4. 9.1.4 Phase III | |
  5. 9.1.5 Phase IV |
2. 9.2 By Service Provider | |
  1. 9.2.1 In-House | |
  2. 9.2.2 Contract Outsourcing |
3. 9.3 By Type of Reporting | |
  1. 9.3.1 Spontaneous Reporting | |
  2. 9.3.2 Intensified ADR Reporting | |
  3. 9.3.3 Targeted Spontaneous Reporting | |
  4. 9.3.4 Cohort Event Monitoring | |
  5. 9.3.5 EHR Mining |
4. 9.4 By End User | |
  1. 9.4.1 Pharmaceutical Companies | |
  2. 9.4.2 Biotechnology Companies | |
  3. 9.4.3 Medical Device Manufacturers | |
  4. 9.4.4 Hospitals | |
  5. 9.4.5 Others
10 Competitive Landscape |
1. 10.1 Market Concentration Analysis (2026) |
2. 10.2 Competitive Benchmarking Matrix |
3. 10.3 Company Profiles | |
  1. 10.3.1 IQVIA | |
  2. 10.3.2 Accenture | |
  3. 10.3.3 Cognizant | |
  4. 10.3.4 ICON plc | |
  5. 10.3.5 Oracle Health Sciences | |
  6. 10.3.6 Parexel | |
  7. 10.3.7 Fortrea | |
  8. 10.3.8 Capgemini | |
  9. 10.3.9 ArisGlobal | |
  10. 10.3.10 Wipro | |
  11. 10.3.11 Tata Consultancy Services | |
  12. 10.3.12 Veeva Systems | |
  13. 10.3.13 ClinChoice
11 Recent News & Developments
12 Report Scope & Methodology |
1. 12.1 Study Period & Base Year |
2. 12.2 Valuation Currency & Conventions |
3. 12.3 Data Sources & Citations
13 Detailed Sources and Citations
14 Frequently Asked Questions
15 LIST OF TABLES
16 LIST OF FIGURES

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Clinical Trial Phase	Pre-Clinical; Phase I; Phase II; Phase III; Phase IV	Phase IV	Pre-Clinical
By Service Provider	In-House; Contract Outsourcing	Contract Outsourcing	Contract Outsourcing
By Type of Reporting	Spontaneous Reporting; Intensified ADR Reporting; Targeted Spontaneous Reporting; Cohort Event Monitoring; EHR Mining	Spontaneous Reporting	EHR Mining
By End User	Pharmaceutical Companies; Biotechnology Companies; Medical Device Manufacturers; Hospitals; Others	Pharmaceutical Companies	Hospitals
By Geography	North America; Europe; Asia-Pacific; South America; Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Clinical Trial Phase

Sub-Segment	Key Trend
Pre-Clinical	Early toxicology documentation shifts left as sponsors build safety infrastructure before first-in-human
Phase I	Intensive monitoring protocols expand for cell and gene therapy candidates
Phase II	Dose-ranging safety characterization increasingly supported by automated coding
Phase III	Pivotal trial volumes drive peak per-study case handling demand.
Phase IV	Perpetual post-authorization obligations create a compounding installed base.

Post-approval work dominates because obligations never expire while trial-phase demand cycles with pipeline timing. Sponsors of advanced therapies are the exception — their pre-clinical and Phase I spend now rivals late-phase budgets on a per-programme basis.

By Service Provider

Sub-Segment	Key Trend
In-House	Retained for signal management and benefit-risk judgment at the largest sponsors
Contract Outsourcing	Majority of global spend; shifting from labour arbitrage toward platform-enabled delivery

The outsourcing boundary is moving up the value chain. Transactional intake left first; analytical work is following as providers demonstrate defensible model governance and inspection-ready documentation.

By Type of Reporting

Sub-Segment	Key Trend
Spontaneous Reporting	Statutory baseline; share erodes gradually despite absolute growth
Intensified ADR Reporting	Tied to specific post-authorization commitments and conditional approvals
Targeted Spontaneous Reporting	Deployed for public health programmes and vaccine campaigns
Cohort Event Monitoring	Applied to new chemical entity launches requiring close observation
EHR Mining	Fastest expansion as distributed data networks become queryable at scale.

Methodology is diversifying away from passive collection. Regulators increasingly expect sponsors to look for signals rather than wait for them, which favours data-rich approaches over notification-dependent ones.

By End User

Sub-Segment	Key Trend
Pharmaceutical Companies	Broadest obligations across geographies and product portfolios
Biotechnology Companies	Biologics and advanced therapy pipelines drive disproportionate per-product spend.
Medical Device Manufacturers	Vigilance requirements converging with pharmaceutical standards under MDR.
Hospitals	Institutional reporting mandates convert providers into budget-holding buyers.
Others	Academic centres, research organizations and public health bodies

Buyer composition is broadening. Hospitals and device manufacturers were peripheral a decade ago; regulatory convergence has made them procurement decision-makers with distinct requirements from traditional pharmaceutical sponsors.

By Region

Sub-Segment	Key Trend
North America	Litigation exposure and Sentinel expansion sustain premium pricing
Europe	GVP remediation and MDR convergence drive multi-year programme spend
Asia-Pacific	Harmonization plus local delivery capacity produces fastest regional growth.
South America	ANVISA modernization anchors regional demand from Brazil
Middle East & Africa	National centre buildout funded by Gulf health transformation programmes

Regional divergence is widening rather than narrowing. Mature markets buy sophistication; emerging markets buy foundational capacity — and providers increasingly need distinct operating models for each.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”